Shandong initiates VBP of non-GQCE drugs in high demand

The Shandong Public Resources Trading Center released a notification in relation to provincial volume-based procurement (VBP). The scope of the notie covers drugs that have not passed generic quality consistency evaluation (GQCE) but are in high clinical demand.

A total of 883 drug varieties are eligible for online procurement. Companies that refuse to commit to price linkage with other locations will face a two-year online procurement ban, as will those that file false price information, or have no distribution capabilities. If manufacturers file for online procurement suspension by themselves and the prices are higher than originally procured online, such products are prohibited from re-procurement online. Thus, allopurinol and 124 other products are ineligible for this VBP.


Related news
Argentina’s Comprehensive Medical Attention Program (PAMI), the largest healthcare program in the country, today adopted a list of medicines that will be provided to patients free of charge, according to a declaration from President Alberto Fernández.
The Brazilian Association of Generic Medicines Industries (PróGenéricos) this week revealed that the fastest growing segment of the pharmaceutical industry during 2019 was the generics market with a 6.4% expansion in units sold, followed by similars (branded generics) and innovative medicines at 4.4% and 2.2% respectively, citing IQVIA data.
Peru’s Ministry of Health (MINSA) last week released the list of generic drugs that private pharmacies must offer to patients, part of an effort to improve healthcare access.
Provincial tendering and health insurance authorities in Henan, Hunan, and Guangxi have all released notifications ordering local hospitals to draw up volume-usage data in preparation for the next round of the volume-based procurement (VBP) program.
The Shanghai Pharmaceutical Affairs Bureau released two lists of drugs retained for procurement in the Sunshine Medical Procurement All-In-One program, with 139 for medical institutions and 113 for hospitals.
Recent news
The National Medical Products Administration (NMPA) last week revealed that Celgene’s Abraxane (paclitaxel, albumin bound) would lose its import clearance after agency inspectors uncovered manufacturing issues at the Fresenius Kabi plant responsible for manufacturing the drug. The news impacts Chinese biotech BeiGene Inc., which generated around USD 100 million with Abraxane in China as the drug's marketing agent under license from Celgene.
  • 1585666816337
  • China
Pfizer subsidiary Wyeth this week obtained a marketing approval from Brazil's National Health Surveillance Agency (ANVISA) for its iron replacement therapy Monofer (ferric derisomaltose), as GBI analysis shows.
Hugo Sigman, founder of of Argentina-based group Insud Pharma, last week commented on Argentina’s biopharmaceutical industry as the COVID-19 pandemic puts the health sector to test.
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA:600196; HKG:02196) released its Q4 2019 financial report.
According to GBI analysis, Mexico’s Federal Commission for the Protection against Health Risks (COFEPRIS) has published recent market approvals for Swiss major Novartis subsidiary Sandoz’s Arasamila (rituximab), Japan-based Daiichi Sankyo’s factor Xa (FXa) inhibitor Lixiana (edoxaban), and compatriot Takeda branch Baxalta’s antihemophilic Adynovate (rurioctocog alfa pegol).
GoBroad Healthcare Group broke ground on construction of a research hospital in Beijing’s Future Science Park this week.
Analytics Snapshot